NVUS - ト―カイ・ファ―マシュ―ティカルズ (Novus Therapeutics Inc.) ト―カイ・ファ―マシュ―ティカルズ

 NVUSのチャート


 NVUSの企業情報

symbol NVUS
会社名 Novus Therapeutics Inc (ト―カイ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 ノーバス・セラピーティクス(Novus Therapeutics Inc.)(旧名:Tokai Pharmaceuticals Inc.)は製薬会社である。同社は主に耳、鼻、喉の製品を購入・開発・商業化する。同社は2つのプラットフォームを有する。OP-01フォームプラットフォームは耳・鼻腔・副鼻腔の治療薬の送達ビヒクルとして使用されるために開発され、現在、急性中耳炎に対する改善された治療選択肢として開発されている。OP-02界面活性剤プログラムは健康な中耳を改善・維持するように設計された毎日の鼻スプレーであり、中耳炎患者及び耳管機能不全の患者のための潜在的な治療選択肢として開発されていて、界面活性剤ジパルミトイルホスファチジルコリン及び展着剤コレステリルパルミテートという2つの成分を含む組合せ薬物製品である。同社の製品は鼻孔を通って鼻腔の後部にある耳管の開口部に向かって噴霧される。  ト―カイ・ファ―マシュ―ティカルズは、臨床段階の米国のバイオ医薬品企業。前立腺癌および他のホルモン主導の疾患の治療のための新規の独自の治療法の開発に従事する。薬剤候補「galeterone」は、選択性が高く多標的な経口小分子薬剤候補。去勢抵抗性前立腺癌を有する患者の治療に「galeterone」の当初の開発に焦点を当てる。   Novus Therapeutics Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of products for disorders of the ear, nose, and throat. Its product pipelines include OPO201; OP0101; and OP0102. The company was founded on March 26, 2004 and is headquartered in Irvine, CA.
本社所在地 19900 MacArthur Blvd. Suite 550 Irvine CA 92612 USA
代表者氏名 Keith A. Katkin キース・A・カトキン
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 949-238-8090
設立年月日 38047
市場名 NASDAQ Small Cap
ipoyear 2014年
従業員数 7人
url www.tokaipharmaceuticals.com
nasdaq_url https://www.nasdaq.com/symbol/nvus
adr_tso
EBITDA EBITDA(百万ドル) -11.04300
終値(lastsale) 4.15
時価総額(marketcap) 39101893.45
時価総額 時価総額(百万ドル) 38.72501
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 19.53601
当期純利益 当期純利益(百万ドル) -11.07500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Novus Therapeutics Inc revenues was not reported. Net loss decreased 25% to $6M. Lower net loss reflects General and administrative decrease of 49% to $3.6M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.03 to -$0.70.

 NVUSのテクニカル分析


 NVUSのニュース

   Novus Therapeutics Completes Enrollment of Phase 2a Trial of OP0201 in Pediatric Patients with Acute Otitis Media  2020/03/02 11:30:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)---- $NVUS #otitismedia--Novus Therapeutics completes enrollment of phase 2a trial in patients with acute otitis media (C-006) and expects to report data by early June 2020.
   Novus Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds  2020/01/10 22:19:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)---- $NVUS #otitismedia--Novus Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds
   Novus Therapeutics Reports Third Quarter 2019 Financial Results  2019/11/13 12:30:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)---- $NVUS #earnings--Novus Therapeutics reports third quarter 2019 financial results, Phase 2a data expected in the first half 2020 & participation in investor conferences
   Novus Therapeutics Receives FDA Guidance on OP0201 Phase 2a Study in Patients with Chronic Otitis Media with Effusion  2019/10/29 11:30:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)---- $NVUS #otitismedia--Novus Therapeutics Receives FDA Guidance on OP0201 Phase 2a Study in Patients with Chronic Otitis Media with Effusion
   The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch  2019/10/16 11:06:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 15) Celgene Corporation (NASDAQ: CELG ) Eagle Pharmaceuticals Inc (NASDAQ: EGRX ) Kodiak Sciences Inc (NASDAQ: KOD ) The Medicines Company (NASDAQ: MDCO ) Natera Inc (NASDAQ: NTRA ) Ra Pharmaceuticals Inc (NASDAQ: RARX ) Reata Pharmaceuticals Inc (NASDAQ: RETA ) (announced positive results for a Phase 2 study of its drug to treat Friedreich ataxia) Relmada Therapeutics Inc (NASDAQ: RLMD ) ( announced positive Phase 2 results for drug to treat treatment-resistant depression) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 15) Auris Medical Holding Ltd (NASDAQ: EARS ) BENITEC BIOPHAR/S ADR (NASDAQ: BNTC ) Chimerix Inc (NASDAQ: CMRX ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Heat Biologics Inc (NASDAQ: HTBX ) INmune Bio Inc (NASDAQ: INMB ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Karuna Therapeutics Inc (NASDAQ: KRTX ) Mirum Pharmaceuticals Inc (NASDAQ: MIRM ) Novus Therapeutics Inc (NASDAQ: NVUS ) Orgenesis Inc (NASDAQ: ORGS ) Phio Pharmaceuticals Corp (NASDAQ: PHIO ) Precision BioSciences Inc (NASDAQ: DTIL ) Pulmatrix Inc (NASDAQ: PULM ) Sierra Oncology Inc (NASDAQ: SRRA ) Strongbridge Biopharma plc (NASDAQ: SBBP ) Stocks In Focus Akebia Sues CMS For Restoring Coverage For Kidney-Disease Related Anemia Drug Akebia Therapeutics Inc (NASDAQ: AKBA ) has filed a compliant in federal district court against the Centers of Medicare & Medicaid Service and the U.S.
   Novus Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds  2020/01/10 22:19:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)---- $NVUS #otitismedia--Novus Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds
   Novus Therapeutics Reports Third Quarter 2019 Financial Results  2019/11/13 12:30:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)---- $NVUS #earnings--Novus Therapeutics reports third quarter 2019 financial results, Phase 2a data expected in the first half 2020 & participation in investor conferences
   Novus Therapeutics Receives FDA Guidance on OP0201 Phase 2a Study in Patients with Chronic Otitis Media with Effusion  2019/10/29 11:30:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)---- $NVUS #otitismedia--Novus Therapeutics Receives FDA Guidance on OP0201 Phase 2a Study in Patients with Chronic Otitis Media with Effusion
   The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch  2019/10/16 11:06:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 15) Celgene Corporation (NASDAQ: CELG ) Eagle Pharmaceuticals Inc (NASDAQ: EGRX ) Kodiak Sciences Inc (NASDAQ: KOD ) The Medicines Company (NASDAQ: MDCO ) Natera Inc (NASDAQ: NTRA ) Ra Pharmaceuticals Inc (NASDAQ: RARX ) Reata Pharmaceuticals Inc (NASDAQ: RETA ) (announced positive results for a Phase 2 study of its drug to treat Friedreich ataxia) Relmada Therapeutics Inc (NASDAQ: RLMD ) ( announced positive Phase 2 results for drug to treat treatment-resistant depression) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 15) Auris Medical Holding Ltd (NASDAQ: EARS ) BENITEC BIOPHAR/S ADR (NASDAQ: BNTC ) Chimerix Inc (NASDAQ: CMRX ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Heat Biologics Inc (NASDAQ: HTBX ) INmune Bio Inc (NASDAQ: INMB ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Karuna Therapeutics Inc (NASDAQ: KRTX ) Mirum Pharmaceuticals Inc (NASDAQ: MIRM ) Novus Therapeutics Inc (NASDAQ: NVUS ) Orgenesis Inc (NASDAQ: ORGS ) Phio Pharmaceuticals Corp (NASDAQ: PHIO ) Precision BioSciences Inc (NASDAQ: DTIL ) Pulmatrix Inc (NASDAQ: PULM ) Sierra Oncology Inc (NASDAQ: SRRA ) Strongbridge Biopharma plc (NASDAQ: SBBP ) Stocks In Focus Akebia Sues CMS For Restoring Coverage For Kidney-Disease Related Anemia Drug Akebia Therapeutics Inc (NASDAQ: AKBA ) has filed a compliant in federal district court against the Centers of Medicare & Medicaid Service and the U.S.
   The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout  2019/10/11 12:14:27 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 10.) The Medicines Company (NASDAQ: MDCO ) Ra Pharmaceuticals Inc (NASDAQ: RARX ) ( announced a deal to be bought by Belgium's UCB) Down In The Dumps (Biotech stocks that hit 52-week lows Oct. 10.) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Alkermes Plc (NASDAQ: ALKS ) Atreca Inc (NASDAQ: BCEL ) AzurRx BioPharma Inc (NASDAQ: AZRX ) (announced CEO departure) BioNano Genomics Inc (NASDAQ: BNGO ) BioTelemetry Inc (NASDAQ: BEAT ) Cellectis SA (NASDAQ: CLLS ) Cerus Corporation (NASDAQ: CERS ) Chimerix Inc (NASDAQ: CMRX ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Clovis Oncology Inc (NASDAQ: CLVS ) Cocrystal Pharma Inc (NASDAQ: COCP ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Dermira Inc (NASDAQ: DERM ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Genprex Inc (NASDAQ: GNPX ) Gossamer Bio Inc (NASDAQ: GOSS ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Homology Medicines Inc (NASDAQ: FIXX ) Hoth Therapeutics Inc (NASDAQ: HOTH ) Jaguar Health Inc (NASDAQ: JAGX ) (announced plans to explore options to license Mytesi in China) Meridian Bioscience, Inc. (NASDAQ: VIVO ) MOTIF BIO PLC/S ADR (NASDAQ: MTFB ) MOTIF BIO PLC/S ADR (: MTFB) Novus Therapeutics Inc (NASDAQ: NVUS ) Obalon Therapeutics Inc (NASDAQ: OBLN ) Onconova Therapeutics Inc (NASDAQ: ONTX ) Orgenesis Inc (NASDAQ: ORGS ) PAVmed Inc (NASDAQ: PAVM ) Precision BioSciences …
   Novus Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds  2020/01/10 22:19:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)---- $NVUS #otitismedia--Novus Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds
   Novus Therapeutics Reports Third Quarter 2019 Financial Results  2019/11/13 12:30:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)---- $NVUS #earnings--Novus Therapeutics reports third quarter 2019 financial results, Phase 2a data expected in the first half 2020 & participation in investor conferences
   Novus Therapeutics Receives FDA Guidance on OP0201 Phase 2a Study in Patients with Chronic Otitis Media with Effusion  2019/10/29 11:30:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)---- $NVUS #otitismedia--Novus Therapeutics Receives FDA Guidance on OP0201 Phase 2a Study in Patients with Chronic Otitis Media with Effusion
   The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch  2019/10/16 11:06:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 15) Celgene Corporation (NASDAQ: CELG ) Eagle Pharmaceuticals Inc (NASDAQ: EGRX ) Kodiak Sciences Inc (NASDAQ: KOD ) The Medicines Company (NASDAQ: MDCO ) Natera Inc (NASDAQ: NTRA ) Ra Pharmaceuticals Inc (NASDAQ: RARX ) Reata Pharmaceuticals Inc (NASDAQ: RETA ) (announced positive results for a Phase 2 study of its drug to treat Friedreich ataxia) Relmada Therapeutics Inc (NASDAQ: RLMD ) ( announced positive Phase 2 results for drug to treat treatment-resistant depression) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 15) Auris Medical Holding Ltd (NASDAQ: EARS ) BENITEC BIOPHAR/S ADR (NASDAQ: BNTC ) Chimerix Inc (NASDAQ: CMRX ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Heat Biologics Inc (NASDAQ: HTBX ) INmune Bio Inc (NASDAQ: INMB ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Karuna Therapeutics Inc (NASDAQ: KRTX ) Mirum Pharmaceuticals Inc (NASDAQ: MIRM ) Novus Therapeutics Inc (NASDAQ: NVUS ) Orgenesis Inc (NASDAQ: ORGS ) Phio Pharmaceuticals Corp (NASDAQ: PHIO ) Precision BioSciences Inc (NASDAQ: DTIL ) Pulmatrix Inc (NASDAQ: PULM ) Sierra Oncology Inc (NASDAQ: SRRA ) Strongbridge Biopharma plc (NASDAQ: SBBP ) Stocks In Focus Akebia Sues CMS For Restoring Coverage For Kidney-Disease Related Anemia Drug Akebia Therapeutics Inc (NASDAQ: AKBA ) has filed a compliant in federal district court against the Centers of Medicare & Medicaid Service and the U.S.
   The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout  2019/10/11 12:14:27 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 10.) The Medicines Company (NASDAQ: MDCO ) Ra Pharmaceuticals Inc (NASDAQ: RARX ) ( announced a deal to be bought by Belgium's UCB) Down In The Dumps (Biotech stocks that hit 52-week lows Oct. 10.) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Alkermes Plc (NASDAQ: ALKS ) Atreca Inc (NASDAQ: BCEL ) AzurRx BioPharma Inc (NASDAQ: AZRX ) (announced CEO departure) BioNano Genomics Inc (NASDAQ: BNGO ) BioTelemetry Inc (NASDAQ: BEAT ) Cellectis SA (NASDAQ: CLLS ) Cerus Corporation (NASDAQ: CERS ) Chimerix Inc (NASDAQ: CMRX ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Clovis Oncology Inc (NASDAQ: CLVS ) Cocrystal Pharma Inc (NASDAQ: COCP ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Dermira Inc (NASDAQ: DERM ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Genprex Inc (NASDAQ: GNPX ) Gossamer Bio Inc (NASDAQ: GOSS ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Homology Medicines Inc (NASDAQ: FIXX ) Hoth Therapeutics Inc (NASDAQ: HOTH ) Jaguar Health Inc (NASDAQ: JAGX ) (announced plans to explore options to license Mytesi in China) Meridian Bioscience, Inc. (NASDAQ: VIVO ) MOTIF BIO PLC/S ADR (NASDAQ: MTFB ) MOTIF BIO PLC/S ADR (: MTFB) Novus Therapeutics Inc (NASDAQ: NVUS ) Obalon Therapeutics Inc (NASDAQ: OBLN ) Onconova Therapeutics Inc (NASDAQ: ONTX ) Orgenesis Inc (NASDAQ: ORGS ) PAVmed Inc (NASDAQ: PAVM ) Precision BioSciences …

 関連キーワード  (医薬品 米国株 ト―カイ・ファ―マシュ―ティカルズ NVUS Novus Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)